Anteris Raises $320M in Dual Offerings to Fuel Heart Valve Expansion

Event summary

  • Anteris closed a $230M public offering of 40M common shares at $5.75/share, including underwriters' option.
  • Concurrent $90M private placement to Medtronic at same price raised total proceeds to ~$320M.
  • Funds will support PARADIGM Trial for DurAVR® THV and expand manufacturing capabilities.
  • Proceeds also allocated to v2vmedtech R&D and general corporate purposes.
  • Offering conducted under SEC Form S-3 registration effective January 8, 2026.

The big picture

Anteris' $320M capital raise positions it for aggressive expansion in the transcatheter heart valve market, where Medtronic and Edwards Lifesciences dominate. The funding supports both clinical validation of its biomimetic technology and manufacturing capacity, critical for competing in a space demanding both innovation and operational scale. The Medtronic investment suggests validation of Anteris' approach, though the company must now demonstrate superior clinical outcomes to capture market share.

What we're watching

Clinical Milestones
The pace at which the PARADIGM Trial enrolls patients will determine DurAVR® THV's regulatory timeline.
Competitive Positioning
Whether Anteris can differentiate its biomimetic valve technology against established competitors.
Capital Deployment
How effectively Anteris balances manufacturing scale-up with ongoing R&D investment.